Epoch Investment Partners Inc. Acquires 10,190 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Epoch Investment Partners Inc. has increased its holdings in Regeneron Pharmaceuticals by 5.2%, owning a total of 207,456 shares worth approximately $131.6 million.
• Regeneron reported a quarterly earnings per share (EPS) of $12.89, significantly exceeding analysts' expectations of $8.43, with revenues of $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, which will be paid on September 3rd, representing an annual yield of 0.6%.

Epoch Investment Partners Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 207,456 shares of the biopharmaceutical company's stock after purchasing an additional 10,190 shares during the quarter. Epoch Investment Partners Inc. owned approximately 0.19% of Regeneron Pharmaceuticals worth $131,575,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares during the period. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $27,000. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $7.35 during trading on Thursday, reaching $579.61. 616,549 shares of the stock traded hands, compared to its average volume of 1,082,231. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,210.97. The business has a fifty day simple moving average of $555.84 and a two-hundred day simple moving average of $588.67. The company has a market capitalization of $61.43 billion, a price-to-earnings ratio of 14.61, a P/E/G ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm earned $11.56 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Citigroup reiterated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Finally, Sanford C. Bernstein upped their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.